New hope for tough lymphoma: experimental drug shows promise
NCT ID NCT03494179
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called ICP-022 in 106 adults with mantle cell lymphoma that had come back or stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check its safety. The approach focuses on controlling the disease rather than curing it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Province Cancer Hospital
Hefei, Anhui, 230009, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 102206, China
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
-
Guangzhou First People's Hospital
Guangzhou, Guangdong, 510180, China
-
Henan Provincial People's Hospital
Zhengzhou, Henan, 450003, China
-
Henan Tumor Hospital
Zhengzhou, Henan, 450008, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130012, China
-
Liaoning Cancer Hospital and Institute
Shenyang, Liaoning, 110042, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100191, China
-
Qilu Hosptial of Shandong University
Jinan, Shandong, 250012, China
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266071, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
-
The First Affiliated Hospital of Zhengjiang University
Hangzhou, Zhejiang, 310003, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Hospital of China Medical University
Shenyang, Liaojing, 110001, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050011, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310052, China
-
The Second Hospital of Dalian Medical University
Dalian, Liaoning, 116044, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Tongji Hospital
Wuhan, Hubei, 430030, China
-
West China Hospital,Sichuan University
Chengdu, Sichuan, 610041, China
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
-
Xin Hua Hospital Affiated to Shanghai Jiao Tong University School of Medicin
Shanghai, Shanghai Municipality, 200092, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer biopsy predict who responds to a new immunotherapy?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?